Pneumonia Vaccine Market size is anticipated to grow at $4.5 billion till 2027, increasing at a CAGR of 4.76% during the forecast period 2020-2027. Pneumonia is an illness results into lung contamination in both the lungs due to the bacterial viruses and organisms. Pneumonia causes irritation around the sacs also referred as alveoli of the lungs results into causing breathing problems as alveoli fills with pus. Pneumococcal illnesses commonly found in young children but elder ones and adults are also more prone to this illness and even death. To get rid of the illness, pneumococcal vaccines are given to the children smaller than 2 years and to the adults. Such vaccines give relief from the bacteria, which make lungs infected by creating immunity in people. This vaccine has the potent to fight against 13 kinds of pneumococcal bacteria causing infection to the lungs. Pneumococcal polysaccharide vaccine is also referred as Pneumovax 23 (PPV-23). This vaccine is the first pneumococcal vaccine and crucial landmark in medical history derived from a capsular polysaccharide. This vaccine is hugely given to the adults who are at high risk. There are two vaccines types available. A conjugate vaccine contains polysaccharide antigen, which has the potent to improve the vaccine stability and efficacy. This vaccine segment greatly contributes towards the global pneumonia vaccine market growth. Infants and Children of 6 weeks to 5 years of age can take this vaccine for the prevention of pneumonia. However, the longer timetables necessary for the production of pneumococcal vaccines, as well as the greater costs associated with vaccine research, are impeding the market’s global expansion. Moreover, throughout the projected period, the development of protein-based vaccines for pneumonia is expected to generate chances for market advancement.